SC 13G/A | 2024-02-09 | DIMENSIONAL FUND ADVISORS LP | PDL BIOPHARMA, INC. | 7,392,656 | 6.5% | EDGAR |
SC 13G/A | 2023-02-10 | DIMENSIONAL FUND ADVISORS LP | PDL BIOPHARMA, INC. | 7,426,503 | 6.5% | EDGAR |
SC 13G/A | 2022-02-08 | DIMENSIONAL FUND ADVISORS LP | PDL BIOPHARMA, INC. | 7,458,893 | 6.5% | EDGAR |
SC 13G/A | 2021-02-12 | DIMENSIONAL FUND ADVISORS LP | PDL BIOPHARMA, INC. | 7,667,597 | 6.7% | EDGAR |
SC 13G/A | 2021-02-11 | RENAISSANCE TECHNOLOGIES LLC | PDL BIOPHARMA, INC. | 0 | 0.0% | EDGAR |
SC 13G/A | 2021-02-11 | BRANDES INVESTMENT PARTNERS, LP | PDL BIOPHARMA, INC. | 7,046,701 | 6.2% | EDGAR |
SC 13D | 2021-01-11 | Silver Point Capital L.P. | PDL BIOPHARMA, INC. | - | - | EDGAR |
SC 13G/A | 2021-01-11 | Park West Asset Management LLC | PDL BIOPHARMA, INC. | 14,397,212 | 12.6% | EDGAR |
SC 13G | 2020-12-16 | Silver Point Capital L.P. | PDL BIOPHARMA, INC. | 13,513,460 | 11.8% | EDGAR |
SC 13G/A | 2020-08-28 | Park West Asset Management LLC | PDL BIOPHARMA, INC. | 6,717,259 | 5.9% | EDGAR |
SC 13G | 2020-08-28 | Park West Asset Management LLC | PDL BIOPHARMA, INC. | 5,793,497 | 5.1% | EDGAR |
SC 13D/A | 2020-05-26 | PDL BIOPHARMA, INC. | Evofem Biosciences, Inc. | 3,333,334 | 6.3% | EDGAR |
SC 13D/A | 2020-03-10 | ENGINE CAPITAL, L.P. | PDL BIOPHARMA, INC. | 2,563,854 | 2.2% | EDGAR |
SC 13D/A | 2020-02-28 | ENGINE CAPITAL, L.P. | PDL BIOPHARMA, INC. | 3,969,421 | 3.5% | EDGAR |
SC 13G/A | 2020-02-13 | RENAISSANCE TECHNOLOGIES LLC | PDL BIOPHARMA, INC. | 8,170,631 | 7.2% | EDGAR |
SC 13G/A | 2020-02-12 | VANGUARD GROUP INC | PDL BIOPHARMA, INC. | 5,523,952 | 4.8% | EDGAR |
SC 13G/A | 2020-02-12 | DIMENSIONAL FUND ADVISORS LP | PDL BIOPHARMA, INC. | 9,530,949 | 8.4% | EDGAR |
SC 13G/A | 2020-02-05 | BlackRock Inc. | PDL BIOPHARMA, INC. | 10,775,002 | 9.4% | EDGAR |
SC 13G | 2020-01-09 | BRANDES INVESTMENT PARTNERS, LP | PDL BIOPHARMA, INC. | 5,811,080 | 5.1% | EDGAR |
SC 13D | 2019-10-23 | ENGINE CAPITAL, L.P. | PDL BIOPHARMA, INC. | 3,827,459 | 3.4% | EDGAR |